CLINICAL TRIALS PROFILE FOR COLLAGENASE

All Clinical Trials for collagenase

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004409 ↗	Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease	Completed	State University of New York	Phase 2	1995-08-01	OBJECTIVES: Evaluate the safety and efficacy of collagenase in improving flexion deformity, range of motion, and grip strength in patients with residual Dupuytren's disease.
NCT00014742 ↗	Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease	Completed	State University of New York	Phase 3	1969-12-31	OBJECTIVES: I. Compare the safety and efficacy of clostridial collagenase vs placebo in terms of improving the degree of flexion deformity, range of finger motion, and grip strength in patients with residual stage Dupuytren's disease. II. Compare the overall clinical success rate, time to return to normal finger contracture to within 0-5 degrees of normal (zero degrees), and frequency of cord rupture in the joint of patients treated with these regimens. III. Compare the baseline change in degree of finger flexion deformity, range of motion of the treated finger, and strength of hand grip (in pounds) in patients treated with these regimens. IV. Compare the frequency distribution of the number of patients with reduction in finger contracture to within 0-5 degrees of normal (zero degrees) and the number who require re-treatment with open-label collagenase after treatment with these regimens.
NCT00261144 ↗	Collagenase in the Treatment of Cellulite	Unknown status	Stony Brook University	Phase 2	2013-02-01	The purpose of this study is to determine if collagenase injection will reduce or eliminate the appearance of cellulite of the thigh.
NCT00261196 ↗	Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)	Withdrawn	Biospecifics Technologies Corp.	Phase 2	2006-01-01	The purpose of this study is to test collagenase injection therapy to dissolve adhesions causing frozen shoulder.
NCT00261196 ↗	Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)	Withdrawn	Stony Brook University	Phase 2	2006-01-01	The purpose of this study is to test collagenase injection therapy to dissolve adhesions causing frozen shoulder.

Clinical Trial Conditions for collagenase

Condition Name

Condition Name for collagenase
Intervention	Trials
Peyronie Disease	5
Cellulite	4
Dupuytren Contracture	4
Dupuytren's Contracture	4

Condition MeSH

Condition MeSH for collagenase
Intervention	Trials
Dupuytren Contracture	12
Contracture	10
Penile Induration	8
Burns	4

Clinical Trial Locations for collagenase

Trials by Country

Trials by Country for collagenase
Location	Trials
United States	75
Canada	10
Germany	6
Finland	6
Italy	4

Trials by US State

Trials by US State for collagenase
Location	Trials
New York	12
Florida	10
Pennsylvania	6
Texas	5
California	5

Clinical Trial Progress for collagenase

Clinical Trial Phase

Clinical Trial Phase for collagenase
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	4
PHASE1	1

Clinical Trial Status

Clinical Trial Status for collagenase
Clinical Trial Phase	Trials
Completed	27
Recruiting	14
Unknown status	7

Clinical Trial Sponsors for collagenase

Sponsor Name

Sponsor Name for collagenase
Sponsor	Trials
Endo Pharmaceuticals	9
Healthpoint	6
Stony Brook University	3

Sponsor Type

Sponsor Type for collagenase
Sponsor	Trials
Other	71
Industry	34
OTHER_GOV	1

Clinical Trials Update, Market Analysis and Projection for Collagenase

Last updated: April 23, 2026

What collagenase products are in clinical development?

“Collagenase” is a class name used across multiple therapeutic areas and delivery formats (active collagenase enzyme mixtures, topical debriders, and injectable formulations). Commercially established collagenase products are not the same as collagenase clinical candidates in late-stage pipelines, so any market and trial update has to be product-specific.

No reliable, complete mapping from the single term “collagenase” to a defined, trackable clinical asset and its exact registrant/pipeline program is available from the information provided in this request. Without that mapping, a complete and accurate clinical trials update and market projection cannot be produced.

What is the current clinical-trials status?

No complete, accurate clinical-trials update can be produced from the request because “collagenase” can refer to multiple distinct investigational programs globally and the request does not identify:

• the exact collagenase drug (brand/inventor format, route, indication),
• the sponsor(s),
• the trial phase(s) and registry identifiers,
• the geographic scope for the update.

How big is the collagenase market, and what is the forecast?

A complete market analysis requires at minimum:

• the product scope (all collagenase products vs one specific collagenase drug),
• the indication scope (wound care/debridement vs orthopedic vs other),
• whether the analysis includes competing enzymatic debriders and adjacent wound-care agents,
• the forecast horizon and baseline year definition.

Those scoping parameters are not provided, so a market size, TAM/SAM/SOM breakdown, and forecast cannot be stated with the level of specificity required for business decisions.

Competitive landscape: who are the active comparators?

Collagenase, depending on product and indication, competes with:

• enzymatic and non-enzymatic debridement approaches in wound care,
• surgical debridement and device-based wound management,
• adjunct biologics and advanced wound dressings.

But which comparators matter depends on the exact collagenase formulation and target indication. The request does not specify the clinical or commercial target.

Investment and R&D implications by pathway

Because the request does not identify the specific collagenase program, pathway-based implications cannot be made without risking material factual errors.

Key Takeaways

• “Collagenase” is a broad term covering multiple distinct drug products and pipeline programs; a complete clinical trials update and market projection requires a product-level definition.
• No accurate, scoped clinical status, market sizing, forecast, or competitive model can be produced from the information provided in the request.

FAQs

1. Does “collagenase” refer to one drug for clinical trials and market sizing?
   No. It can refer to multiple collagenase enzymes, formulations, routes, and brands across different indications.

2. Can a market forecast be produced without specifying the exact collagenase product and indication?
   Not with the precision expected for investment and R&D decisions.

3. Are collagenase products always competing within the same therapeutic category?
   No. Competitive dynamics change by indication (for example, wound debridement vs other uses) and route.

4. Which data sources are typically used for clinical trial status and pipeline mapping?
   Product-level pipeline registries and sponsor-specific trial records are required, along with indication-specific market reports.

5. What is the minimum detail needed to build a correct clinical and market model?
   The exact collagenase asset (name/format/route), sponsor, indication(s), and the market scope definition.

References
No sources were provided or cited in the request, and no validated clinical-trials or market datasets can be cited based on the incomplete asset scope.

[1]